Current Report
Filed: 2026-01-14
Key Insights
- AbCellera Biologics announced the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for its lead drug candidate, ABCL635.
- The company has posted an updated corporate presentation to its investor relations website, which it may use in future communications or conferences.
- The filing does not contain any financial information or material business updates, suggesting this is a routine regulatory filing.